跳至主要内容
临床试验/CTRI/2010/091/002939
CTRI/2010/091/002939未知3 期

A prospective, controlled, randomized, open, comparative, parallel, 2 - arm study to evaluate the efficacy and safety of FDC tablet of Aceclofenac 200 mg and Thiocolchicoside 16 mg SR versus FDC tablet of Aceclofenac 100 mg and Thiocolchicoside 8 mg IR in patients suffering from painful muscle spasms associated with musculoskeletal systems.

Themis Medicare Limited Udyog Nagar S V Road Goregaon West Mumbai3 个研究点 分布在 1 个国家目标入组 200 人开始时间: 待定

试验速览

阶段
3 期
发起方
入组人数
200
试验地点
3
主要终点
Pain intensity (recorded on VAS), tenderness (graded from 0 to 3), Joint Mobility (recorded on VAS), Spasm relief (recorded on VAS), need for rescue medication (number of episodes patient needed T. Paracetamol)Time needed for the patient to be symptom free

研究概览

简要总结

A prospective, controlled, randomized, open, comparative, parallel, 2-arm study to evaluate the efficacy and safety of FDC tablet of Aceclofenac 200 mg and Thiocolchicoside 16 mg SR verus FDC tablet of Aceclofenac 100 mg and Thiocolchicoside 8 mg IR in patients suffering from painful muscle spasms associated with musculoskeletal systems.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Patients of either sex in the age group between 18 to 70 years.
  • Patients painful muscle spasms and contractions associated with cervical and lumbar spondylosis, rheumatoid arthritis, osteoarthritis, blunt superficial trauma, low back pain.
  • Subjects who provide a written informed consent to abide by the study requirements.

排除标准

  • Patients with painful muscle spasms associated with musculoskeletal systems, who need parenteral therapy / surgery / hospital admission for management.
  • Patients treated with any other oral / parenteral muscle relaxants, analgesics (NSAIDS & Opioids) medications within 1 week prior to the study.
  • Patients suffering from organic neurological disorders (Upper motor neuron disorders, cerebral palsy, pyramid tract injury, multiple sclerosis, cerebrovascular events, myelopathy, encephalomyelitis, etc), peripheral vascular diseases (arteriosclerosis obliterans, diabetic angiopathy, thrombangiitis obliterans, Raynaud's disease, diffuse scleroderma) as well as syndromes developing on the basis of impaired vascular innervation (acrocyanosis, dysbasia angioneurotica intermittent); Little's diseases and other encephalopathies accompanied by dystonia.
  • Patients suffering from myasthenia gravis or myopathies with muscle weakness as the prominent symptom.
  • Patients with known hypersensitivity to any of the ingredients of the test / comparator formulation.
  • Patients with severe cardiac, hepatic, gastrointestinal, renal, pulmonary and skin diseases.
  • Pregnant and lactating females.
  • Simultaneous participation in another clinical study.

结局指标

主要结局

Pain intensity (recorded on VAS), tenderness (graded from 0 to 3), Joint Mobility (recorded on VAS), Spasm relief (recorded on VAS), need for rescue medication (number of episodes patient needed T. Paracetamol)Time needed for the patient to be symptom free

时间窗: 0, 4 days, 7 days, 14 days

次要结局

  • Digit / alphabet cancellation test, reaction time : auditory and visual using the reaction time apparatus, flicker fusion frequency using the flicker fusion apparatus, measurement of hand grip strength, ADR recording, blood investigations(0, 14 days)

研究者

发起方
Themis Medicare Limited Udyog Nagar S V Road Goregaon West Mumbai
申办方类型
Pharmaceutical industry-Indian

研究点 (3)

Loading locations...

相似试验